# salud mental

# Pilot Feasibility Study of an Individualized Cognitive Rehabilitation Program in Mexican Adults with Mild Dementia

Sara Gloria Aguilar-Navarro, María Guadalupe Iris Palacios-Hernández, María Gu

- Departamento de Geriatría, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.
- <sup>2</sup> INSERM, Bordeaux Population Health Research Center, UMR U1219, University of Bordeaux, Bordeaux, France.
- <sup>3</sup> Departamento de Neurología y Psiquiatría, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

# Correspondence:

Alberto José Mimenza-Alvarado
Departamento de Geriatría, Instituto
Nacional de Ciencias Médicas y
Nutrición Salvador Zubirán.
Vasco de Quiroga 15, Alcaldía
Tlalpan, Ciudad de México, CP
14080, México.
Phone: +52 (55) 5487-0900 Ext:

 ${\it Email: a.mimenza@hotmail.com}$ 

Received: 24 January 2023 Accepted: 16 November 2023

#### Citation:

Aguilar-Navarro, S. G., Palacios-Hernández, M. G. I., Ouvrard, C., Gutiérrez-Gutiérrez, L. A., & Mimenza-Alvarado, A. J. (2024). Pilot Feasibility Study of an Individualized Cognitive Rehabilitation Program in Mexican Adults with Mild Dementia. Salud Mental, 47(5), 239-248.

**DOI:** 10.17711/SM.0185-3325.2024.028



#### **ABSTRACT**

Introduction. Dementia is a global public health problem, for which there is currently no cure. The increasing number of non-pharmacological interventions for the management of dementia challenges us to provide evidence-based care. Objective. To evaluate the feasibility of an individualized, cognitive rehabilitation program based on the French ETNA3 trial in Mexican subjects over fifty-five with mild Alzheimer's dementia and their caregivers who live in the community. Method. Non-randomized feasibility study. The intervention consisted of a twelve-month cognitive rehabilitation program, divided into eighteen ninety-minute sessions, administered by trained psychologists, and standardized according to the French ETNA3 program. To assess its feasibility, we determined the percentage of eligibility, acceptability, retention, and compliance and evaluated the adverse effects and degree of satisfaction in patients and their caregivers. Results. Thirty-two people with dementia and their caregivers agreed to participate. The mean age of the participants was 80 ± 8 years, the majority (72%) were women, and 78% had had five or more years of schooling. At twelve months, twenty-eight subjects (87%) completed the program with 100% compliance with the scheduled sessions. Discussion. This study shows the feasibility of an individualized cognitive rehabilitation program based on ETNA3 for Mexican subjects with mild dementia and their caregivers. Conclusion. More studies are required to evaluate the importance of trained therapists and caregiver support in achieving significant cognitive and functional changes in patients.

Keywords: Cognitive rehabilitation, mild dementia, reminiscence therapy, elderly adults.

# **RESUMEN**

Introducción. La demencia es un problema mundial de salud pública, actualmente no existe una cura. El creciente número de intervenciones no farmacológicas para el manejo de la demencia nos desafía a brindar atención basada en evidencia. Objetivo. Evaluar la factibilidad de llevar a cabo un programa individualizado de rehabilitación cognitiva derivado del ensayo francés ETNA3 en sujetos mexicanos mayores de 55 años con demencia leve tipo Alzheimer y sus cuidadores que viven en la comunidad. Método. Estudio de factibilidad no aleatorizado, la intervención consistió en un programa de rehabilitación cognitiva de 12 meses, distribuido en 18 sesiones de 90 minutos, fue administrado por psicólogos capacitados y estandarizados en base al programa francés ETNA3. Para evaluar la factibilidad se determinó el porcentaje de elegibilidad, aceptabilidad, retención y cumplimiento, se evaluaron los efectos adversos y el grado de satisfacción en los pacientes y sus cuidadores. Resultados. Aceptaron participar 32 personas con demencia y sus cuidadores, la edad media de los participantes fue 80 ± 8 años, la mayoría (72 %) eran mujeres y el 78% tenían 5 o más años de escolaridad. A los 12 meses, 28 sujetos (87 %) completaron el programa con 100 % de cumplimiento a las sesiones programadas. Discusión. Este estudio muestra la factibilidad de un programa de rehabilitación cognitiva individualizado basado en ETNA3 en sujetos mexicanos con demencia leve y sus cuidadores. Conclusiones. Se necesitan más estudios que evalúen la importancia de terapeutas capacitados y del apoyo de cuidadores para lograr cambios cognitivos y funcionales significativos en los pacientes.

Palabras clave: Rehabilitación cognitiva, demencia leve, terapia de reminiscencia, adultos mayores.

# INTRODUCTION

Dementia is a global public health problem affecting approximately fifty-five million people. Due to the aging population, this figure is expected to rise to 152 million by 2050 (Nichols et al., 2022). Alzheimer's disease (AD), a neurodegenerative disorder characterized by progressive memory deficits and disability, is the leading dementia sub-type (DeTure & Dickson, 2019), for which there is currently no cure. In addition to vascular prevention, the current pharmacological approach involves FDA-approved symptomatic therapy that provides limited long-term benefits (Alzheimer's Association, 2016). Approximately 80% of those with cognitive impairment will experience the behavioral and psychological symptoms of dementia at some stage of the disease (Lyketsos et al., 2002). Both dementia patients and their caregivers can benefit from adequate symptom management.

Several non-pharmacological interventions have been proposed to manage neuropsychiatric symptoms and even improve cognitive function to improve the quality of life of patients and caregivers (Livingston et al., 2014). Three types of non-pharmacological cognitive interventions have been developed to improve cognitive functioning in people with dementia. Cognitive stimulation involves non-specific exercises, tasks, and activities such as word games and brain teasers focused on cognitive and social functioning reinforcement (Berg-Weger & Stewart, 2017). Reminiscence therapy in people with dementia, using photographs and everyday items such as music and movies, encourages participants to talk about past experiences and memories, promoting skill retention and mood improvement (Huang et al., 2015). Cognitive training seeks to maintain or improve a particular aspect of cognitive functioning (such as memory or attention) through structured, guided practice provided individually or in a group (Bahar-Fuchs et al., 2013). Cognitive rehabilitation is an individualized intervention focused on a person's needs and includes models that help slow down cognitive decline. Minimizing mental decline also involves using strategies to find, learn, and practice compensation techniques (Choi & Twamley, 2013). Individuals with cognitive impairment and therapists usually work together to achieve key goals (Wilson, 2002). However, a systematic review has confirmed that a single intervention implemented in a group setting does not suffice to meet all a patient's needs. Each person with dementia must be individually assessed and treated accordingly (Meyer & O'Keefe, 2018). Ideally, clinical interventions, often achieved through collaboration between the patient and a close family member, must be tailored to the individual's priorities, needs, and preferences. Individualized intervention is characterized by being delivered by the same trained therapist who knows the diagnosis, stage, and individual characteristics of the person receiving the intervention.

Non-pharmacological interventional studies are characterized by distinct levels of evidence and heterogeneous methodologies. The authors of a literature review stated that these programs were at best comparable to traditional care (Petriwskyj et al., 2016). To our knowledge, there is only one randomized controlled trial (RCT) of individualized cognitive rehabilitation, involving both a person-centered approach and high-quality evidence targets. The Efficacy Assessment of Three Non-Pharmacological Therapies in Alzheimer's Disease (ETNA3) Trial compared the impact of cognitive training, reminiscence therapy in group sessions, and an individualized cognitive rehabilitation program with individualized sessions on the rate of progression of dementia. A two-year follow-up analysis of the 653 AD outpatients who received the latter intervention reported no impact on primary efficacy measures (moderately severe to severe dementia-free survival rates). Moreover, none of the secondary outcomes (such as impairment, functional disability, behavioral disturbance, quality of life, depression, caregiver burden, and resource use) involving group session interventions differed from those of usual care. However, with an individualized cognitive rehabilitation program, reduced functional disability, and a six-month institutionalization delay at twoyear follow-up were observed (Amieva et al., 2016).

Given this evidence, it is essential to determine whether these practices are applicable in settings outside clinical research and in other sociocultural contexts. Countries in Latin America have different resources, cultural and historical features, ethnicities, socioeconomic disparities, and health and economic systems (Aravena et al., 2022). The main objective of this study was therefore to evaluate the feasibility, acceptability, retention, adherence, and satisfaction rates of an individualized cognitive rehabilitation program based on the French ETNA3 study, administered to mild dementia outpatients at a memory clinic in Mexico City.

# **METHOD**

# Participants and setting

We conducted a single-arm clinical trial at the memory clinic of a tertiary-level hospital in Mexico City with non-institutionalized subjects over fifty-five years of age with a diagnosis of mild Alzheimer's disease (AD). The same evaluator (a certified geriatrician or neurologist) performed a clinical and cognitive evaluation using the NINCDS ADRDA (McKhann et al., 2011) and the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria to determine possible or probable AD (Sachdev et al., 2014), whether the person had a caregiver (someone who has contact with the subjects for at least ten hours a week), and the absence of uncontrolled and/or concomitant depression or vascular dementia.

Exclusion criteria included subjects who were unable to read or write, had major depression on the Geriatric Depression Scale, (GDS) > or equal to 6 points, a Hachinski 7 single-item scale score > 2 ( 2 or more indicates a vascular component of cognitive impairment) (Hachinski et al., 2012), with poor chronic disease control (such as heart disease, hypertension, lung disease, liver disease, cancer, and diabetes) or altered vitamin B12 or vitamin D levels.

Since this was an exploratory feasibility study, no sample size calculation was performed, with researchers simply recruiting patients who met the inclusion criteria and agreed to participate in the period from December 2018 to February 2019.

# Recruitment

To determine eligibility, researchers reviewed subjects' records at the memory clinic. Subjects who met the inclusion and exclusion criteria were subsequently contacted via telephone to receive an explanation of the study's characteristics and an invitation to participate. If a person was interested, we scheduled an appointment to confirm their eligibility




Figure 1. Overview of the study protocol.

and ask further questions. Both the subject and caregiver gave their informed consent in writing. The local Ethics Committee approved this protocol.

Figure 1 provides a summary of the protocol followed for recruitment. Eighty-two subjects with mild dementia were initially identified. After a review performed by researchers at the memory clinic for eligibility criteria, only fifty-six were invited to participate. Finally, thirty-two subjects and their caregivers gave their written consent.

#### Intervention

The intervention process followed a standardized procedure to guarantee homogeneity. Three psychologists with experience in the field of dementia were recruited. They received a three-day training program taught by ETNA3 study staff (Amieva et al., 2016). A detailed explanation of the rehabilitation plan and a manual specifying the intervention guidelines were provided. Monthly supervision sessions were also conducted during the study.

The cognitive rehabilitation program consisted of ninety-minute sessions. As shown in Figure 1, during the first three months, these sessions were scheduled weekly (intensive phase), while maintenance sessions were held every six weeks for the following nine months. All evaluations were performed in a doctor's office by the same psychologist originally assigned to each patient.

The cognitive rehabilitation therapy consisted of a program conducted through individual sessions (with the subject and caregiver). The psychologist(s) asked the patient to choose the therapy for each day, after considering their clinical characteristics, including sociodemographic factors, severity of the disease and cognitive and behavioral alterations. In the first two sessions, the following were explored with the patient and their caregiver: the activities (hobbies or crafts) the patient used to enjoy and had stopped doing; the patient's interest in recovering and talking about their life story, from their oldest memories (childhood) to their current ones (reminiscence therapy). It was agreed that the material required to perform each activity would be provided by the patient and their caregiver (such as photographs, sewing materials, and books). The first two sessions were dedicated to selecting tasks related to leisure or daily activities according to the personal objectives and cognitive abilities of each subject. In both therapies, we emphasized the engaging in everyday activities to find strengths that would compensate for deterioration, such as tasks that involve learning information. (such as lists of words, stories, and figures) and the discussion of past activities, events, and experiences enhanced by items such as photographs, familiar items, songs, and personal recordings (Amieva et al., NCT00646269). In the following sessions involving individualized therapy, the patient decided what to do in each session: cognitive therapy or reminiscence.

# Case examples

Case 1: A seventy-nine-year-old housewife, who compulsively washed clothes even though they were clean, all day every day. She had previously enjoyed embroidery, "but I don't know how to do it anymore." She chose cognitive therapy and brought in her unfinished embroidery material. We began to work by trial and error, emphasizing successes and downplaying mistakes. At the same time, we remembered the names of stitches, threads, and lace. The woman stopped washing clothes and began to spend her time embroidering. Case 2. An eighty-five-year-old man, previously engaged in public activity with a large support network for agenda management. Although his main interest had been social activities, he now lived in a state of anhedonia and apathy. Since he had no interest in cognitive activities, he chose reminiscence therapy. We began by talking about his career using positive material obtained from the web. The caregiver provided photographs from his childhood, youth, and adulthood, facilitating the intervention. We also used music and artwork from the Web. His family started to become involved and he began to participate more.

During the first three months, the psychologists contacted the caregivers weekly, urging them to ask questions about the intervention and encouraging them to mention any particular difficulties. They were subsequently called every six weeks during the maintenance phase of the program.

Subjects' demographics (age, sex, education level, occupation, perceived financial status, subjective health status, relationship with caregiver, and living situation) and comorbidities were recorded at baseline. Their cognitive status was evaluated using the Mini-Mental State Examination (MMSE) (Folstein et al., 1975) and the Montreal Cognitive Assessment (MoCA-S) (Aguilar-Navarro et al., 2018). Behavioral symptoms were evaluated using the Neuropsychiatric Inventory (NPI) (Cummings et al., 1994), depressive symptoms using the Geriatric Depression Scale (GDS), (Yesavage et al., 1982), functional capacity with the Disability Assessment for Dementia (DAD), (Gélinas et al., 1999), and quality of life through Quality of Life in Alzheimer's Disease (QoL-AD) (Logsdon & Teri, 2018), while the caregiver burden was assessed with The Zarit Burden Interview (Zarit et al., 1986).

#### Feasibility and Acceptability Evaluation

Feasibility was determined by evaluating the eligibility, acceptability, retention, adherence, and tracking rates of the method. We also evaluated the number of adverse effects and degree of satisfaction. These parameters are described below:

Eligibility rate: Calculated by dividing the number of people diagnosed with mild Alzheimer's dementia at the memory clinic by the number of subjects meeting the inclusion criteria.

- Acceptability rate: Calculated by dividing the number of people who gave their written consent to participate in the study by the number of subjects diagnosed with AD who met the inclusion criteria and were invited to participate.
- Retention rate: Defined as the number of people who remained in the study, in other words, the number of participants who did not drop out of the study divided by the total number of participants recruited.
- Adherence rate: Measured by adding the total number of intervention sessions received by participants divided by the total number of sessions scheduled for the participants included (eighteen sessions for each subject).
- Adverse events: Researchers recorded any adverse events perceived by participants during the intervention, such as emotional distress, acts of aggression during sessions, or changes in emotional functioning.
- Satisfaction: Assessed in subjects and their caregivers through a six-item questionnaire on their
  participation in the study, the information provided, the availability of the researchers, activities
  conducted in the sessions, frequency of sessions,
  and logistical organization rated on a Likert-type
  scale ranging from one (not at all satisfied) to seven (Totally satisfied). The minimum score was six
  points, and the maximum score forty-two.

The study was feasible if the rates had a value of over 50%, as in those reported in previous studies (Orsmond & Cohn, 2015).

#### **Program effectiveness**

Evaluations were conducted at two moments: at baseline and twelve months (at the end of the maintenance phase).

Cognitive status was assessed using the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MOCA) (Folstein et al., 1975; Freitas et al, 2013). Behavioral symptoms were evaluated using the Neuropsychiatric Inventory (NPI) (Cummings et al., 1994), depressive symptoms using the Geriatric Depression Scale (GDS) (Yesavage et al., 1982), functional capacity using the Disability Assessment for Dementia (DAD) (Gélinas et al., 1999), quality of life using the Quality of Life in Alzheimer's Disease (QoL-AD) (Logsdon & Teri, 2018), and caregiver burden using The Zarit Burden Interview (Zarit et al., 1986) at these two points in time.

# **Data analysis**

Categorical variables were described as numbers and proportions, and continuous variables as means, standard deviations (SD), and ranges. We determined the rates of eli-

gibility, acceptability, retention, and adherence, as well as the adverse effects and the subject's degree of satisfaction. We performed a correlation analysis to establish an association between the demographic and clinical variables and the feasibility values (number of sessions and assessments completed) with Spearman's rho test.

Using the Shapiro-Wilk test, we found that the variables did not have a normal distribution. For comparisons before and after the cognitive rehabilitation program (at baseline and twelve months), we used raw scores for all analyses and the Wilcoxon nonparametric test (Dexter, 2013). The effect of the intervention was also based on case studies. Individual scores were plotted for each participant's comparison between baseline and twelve months to visually compare the distribution of results among participants who completed the program, allowing for person-based assessment. Global scores were calculated for each questionnaire and subscale (DAD, MoCA, MMSE). Field notes were collected at the end of each visit and after telephone conversations to record participants' experience with the protocol and any feedback. The efficacy of the intervention and feasibility of the protocol and intervention were evaluated based on the case studies (Blampied, 1999; Thomas, 2011).

The statistical analyses were performed using SPSS vs. 25.

#### **Ethical considerations**

This study protocol was reviewed and approved by the local Ethics Committee of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, (INCMNSZ), approval number [NER-2465]. For this study, both the subjects (or their parent/legal guardian/next of kin) and their caregivers gave their informed consent in writing.

# RESULTS

A total of thirty-two persons living with a major neurocognitive disorder and their caregivers agreed to participate. Table 1 shows the baseline characteristics of the participants. The mean age was  $80.03 \pm 7.8$  years, 72% were women, 78% had completed five or more years of education, and 22% were still working. Twelve subjects were widowed (37.5%), and ten married (31.2%). Most of the caregivers were either offspring (50%) or spouses (25%). Twenty-one participants lived with their caregivers (65.6%). Most of the participants reported good to excellent health (93.7%). The most frequent comorbidity was corrected visual deficit (87.5%), followed by hypertension (62.5%) (Table 1).

At baseline, the mean score for the scales of MMSE was 21.3.  $\pm$  4.3 points, MoCA 14.38  $\pm$  5.3 points, DAD 28.9  $\pm$  5.4 points, Zarit 22.6  $\pm$  13.2 points, NPI 17.94  $\pm$  12,9 points, Qol-AD 36.5  $\pm$  5.07 points, and GDS scale 2.28  $\pm$ 1.7 points

Table 1 Participants' baseline characteristics

Variables	N = 32
Age, median (min – max)	79.0; (56 – 93)
Female, n (%)	23 (71.9)
Years of education, n (%)	
No education	1 (3.1)
1 - 4	6 (18.8)
5 - 9 10 +	11 (34.4) 14 (43.8)
Occupation, <i>n</i> (%)	14 (40.0)
Housewife/man	25 (78.1)
Employed	3 (9.4)
Farmer	1 (3.1)
Other	3 (9.4)
Caregiver, n (%)	0 (05)
Spouse Child	8 (25) 16 (50)
Grandchild	1 (3.1)
Friend	0 (0)
Other	7 (21.9)
Lives with his/her caregiver, n (%)	21 (65.6)
Perceived economic situation, n (%)	
Excellent	4 (12.5)
Very good	4 (12.5)
Good	23 (71.9)
Bad Vary had	1 (3.1) 0 (0)
Very bad Living situation, <i>n</i> (%)	0 (0)
Married	10 (31.2)
Divorced or separated	7 (21.9)
Alone	3 (9.4)
Widowed	12 (37.5)
Common-law union	0 (0)
Subjective health, <i>n</i> (%)	E (4E C)
Excellent Very good	5 (15.6) 6 (18.8)
Good	19 (59.4)
Bad	2(6.2)
Very bad	0 (0)
Comorbidities, n (%)	
Diabetes	10 (31.2)
Hypertension Hypercholesterolemia	20 (62.5) 10 (31.2)
Hypothyroidism	6 (18.8)
Depression	7 (21.9)
Visual impairment	28 (87.5)
Hearing impairment Other	12 (37.5) 21 (65.6)
Initial Evaluation	21 (00.0)
MMSE score ▼ (SD); (min-max)	21.31 (4.32); (16-28)
Functional abilities (DAD score) X (SD);	
(min-max)	28.91 (5.47); (17-38)
Caregiver's burden (Zarit score) X̄ (SD); (min-max )	22.62 (13.29); (0-45)
Behavioral symptoms (NPI total score) SD); $\overline{X}$ (min-max)	17.94 (12.99); 0-43)
Quality of life (QoL-AD) X (SD); (min-	36.50 (5.07); 25-47
max) Depressive symptoms (GDS score) $\overline{X}$	2.28 (1.78); (0-6)
(SD); (min-max)	

Note: MMSE: Mini-Mental State Examination, MoCA: Montreal Cognitive Assessment, NPI: Neuropsychiatric Inventory, GDS: Geriatric Depression Scale, DAD: Disability Assessment for Dementia, QoL-AD: Quality of life in Alzheimer's Disease, Zarit: The Zarit Burden Interview. SD: Standard deviation.

respectively. Of the 28 participants who completed the study, 15 (53%) of the total number of participants showed overall cognitive improvement, (MMSE and MoCA), with seven (25%) participants improving their independence in basic and instrumental activities on the daily activities scales (DAD). However, this did not achieve statistically significant levels (Figure 2).

Of the eighty-two cases with AD discussed at the memory clinic, fifty-six met the inclusion criteria and were contacted. The calculated eligibility rate was 68%.

The acceptability rate was 57%. Of the fifty-six subjects contacted, thirty-two agreed to participate (57%), nineteen declined (34%), and five did not respond (9%).

The retention rate was 87.5%, with 32 subjects entering the study. Four subjects withdrew from the study for various reasons (health issues, the caregiver could not take the subject to the sessions, family problems, and loss of follow-up). In the correlation analysis, a lower initial score on the GDS was associated with a higher retention level. The adherence rate of the twenty-eight subjects who remained in the study was 100%. We planned eighteen sessions for each subject included, providing five hundred and four sessions, some of which were rescheduled due to logistical difficulties or health issues. The caregivers remained highly engaged throughout the program and responded to scheduled follow-up calls. A low negative correlation was observed between baseline behavioral symptom scores and level of adherence, although this was not statistically significant (Table 2).

Subjects or caregivers reported no adverse effects during the intervention.

The mean score on the satisfaction questionnaire for the 28 subjects with dementia who completed the study was 39.7  $\pm$  8 points (representing 94.7% satisfaction) and 40.7  $\pm$  2.2 points for the caregivers (representing 97.1% satisfaction).

Table 3 presents the mean for each outcome measure before and after treatment. Wilcoxon tests revealed no significant differences in measures of cognition (p = .414), quality of life (p = .189), depression symptoms (p = .28), or neuropsychiatric symptoms (p = .421). A lower caregiver burden score was observed, however, which was significant (p = .049).

# DISCUSSION

Feasibility studies can help researchers predict whether a future trial is likely to be productive. This study determined the feasibility of an individualized cognitive rehabilitation program derived from the French ETNA3 study at baseline and 12 months. A previous review of studies conducted in Latin America has reported similar barriers to this study: the cultural assumption that the families of people with dementia should care for them, meaning that their needs are overlooked (Aravena, 2022). Resources vary widely, since in Mexico, there are limited funds and human resources to




Figure 2. Bland-Altman plots comparing DAD (a), MMSE (b), QOL-AD (c), GDS (d), Zarit (e), and NPI (f) scale scores between at baseline and at 12 months evaluation. DAD: The Disability Assessment for Dementia. MMSE: Mini-Mental State Examination. QOL-AD: Quality of life in Alzheimer's Disease. GDS: Geriatric Depression Scale. NPI: Neuropsychiatric Inventory.

Table 2
Correlation between baseline characteristics of the subjects and caregivers with the level of retention and the level of adherence

	Level of Retention		Level of Adherence	
	Spearman´s Rho value	p value	Spearman´s Rho value	p value
Age at inclusion	.158	.388	.092	.616
Years of education	112	.542	.006	.975
Perceived economic situation	108	.558	.058	.751
MMSE score	068	.712	053	.774
GDS score	455	.009	153	.402
Time spent on care	335	.061	138	.452
Zarit score	221	.225	210	.249
NPI score	284	.116	307	.087

Table 3
Differences in scores before and after the intervention

	Pre- Intervention evaluation	Post- Intervention evaluation	
	Mean (SD)	Mean (SD)	p value
MMSE score	21.31 (4.32)	21.14 (4.18)	.844
DAD score	28.91 (5.46)	26.71 (7.35)	.082
Quality of life (QOL-AD)	37.88 (5.17)	34.64 (5.81)	.189
GDS score	2.28 (1.78)	1.68 (1.67)	.280
Zarit score	22.63 (13.29)	18.18 (11.46)	.049
NPI score	17.94 (12.99)	13.54 (13.33)	.421

be able to replicate studies. There is a low rate of diagnosis of dementia in its early stages compared to developed countries as it is considered a normal aging process due to the low level of information on AD, even among the relatives and caregivers of patients with dementia, with treatment focusing on pharmacological measures. In Latin America, the diagnosis is usually made by specialists and only occasionally by a general practitioner (GP), in contrast to European countries, where most patients are diagnosed by a GP (Nitrini, 2020).

In this study, the eligibility rate was 68%, and causes of exclusion were poor control of chronic diseases, concomitant vascular dementia, and depression, reflecting the high degree of comorbidity in the Mexican population, which could play a confounding role in the lack of response to non-pharmacological treatment of dementia.

The study acceptance rate was 57.1%. Understanding the reasons for non-participation in interventional studies is essential because information obtained through these assessments can improve consent rates in future studies. Similar recruitment rates of 49.2% have been reported in previous behavioral trials involving patients and a support person (Trivedi et al., 2013). The most common reasons for not giving consent for physical activity programs are pre-existing medical conditions and lack of interest (Hubbard et al., 2016). Recruiting dyads poses a challenge because both subjects (patient and caregiver) must meet the eligibility criteria and be willing to participate in the sessions planned throughout the trial. A major challenge is encouraging eligible subjects to participate in the study and maintaining engagement in the activities due to the presence and severity of pre-existing diseases, the lack of awareness concerning non-pharmacological interventions, and the existence of misconceptions regarding the value of treatment programs with low expectations of success (Clare et al., 2004; Wigfield & Eccles, 2000).

Participants' level of adherence is an essential component of successful interventional programs, which not only involve training subjects and educational sessions but also the involvement of caregivers and family support systems. Moreover, for cognitive rehabilitation to be attractive and practical, participants' feelings of self-competence and self-efficacy

must be enhanced. These patients could benefit from cognitive behavioral therapy targeting feelings of hopelessness and low expectations of success. In this study, the adherence rate was 100%, which is higher than the average reported in previous studies (Trivedi et al., 2013). This suggests that subjects remained highly involved throughout the study, due to the close support of their caregivers, who provided a basic level of stimulation. In our research, in addition to educating caregivers about neurocognitive disorders, it was also essential to encourage them to answer questions or share experiences with their patients or each other. This was done at the end of each of the sessions individually. Subjects who dropped out of the study had more behavioral symptoms, which could have contributed to differences between participants and caregivers and prevented them from continuing with the study. It has previously been reported that, together with the self-perception of worsening health and longer care time, dropout rates are associated with the physical and psychological problems of caregivers, which could prevent them from taking the person with dementia to the center for rehabilitation sessions (Custodio et al., 2014). More depression symptoms were observed among subjects who failed to complete the planned sessions, as has been reported in studies of predictors of treatment adherence (Gebrie & Ford., 2019).

In this study, although no statistically significant differences were achieved in the overall cognitive evaluation due to the statistical power of the sample, some individual changes of improvement are observed in the case-by-case study, with stability in the mean scores at twelve months. The neural mechanisms underlying the positive influence of non-pharmacological treatment remain unclear. Enhanced brain plasticity, the brain's ability to restructure itself in response to stressors, may be an essential component of the mechanism responsible for the cognitive improvements associated with rehabilitation interventions. In one study, serum brain-derived neurotrophic factor (BDNF) levels increased in the intervention group compared to basal conditions, which was also related to cognitive improvements (Jeong et al., 2016). The latter results suggest that functional deficits could be offset by improving the efficiency of the neural network (Shigihara et al., 2020).

In this study, a significant decrease in caregiver burden was observed, suggesting that caregivers feel less tired helping their patients, together with a decrease in behavioral symptoms that was not statistically significant (Kurth et al., 2021).

Despite potential side effects, drug treatments dominate the dementia treatment landscape. In particular, antipsychotics are associated with an increased risk of stroke and death (Ralph & Espinet, 2018). The efficacy of non-pharmacological therapy in improving cognition or slowing down the progression of cognitive decline has been confirmed, which is why non-pharmacological therapy constitutes a potentially effective complementary treatment for dementia (Wang et al., 2020).

Since the evolution of neurocognitive disorders is heterogeneous, treatment approaches must be individually tailored. Interventions should ideally be designed for both patients and their family environment. The individualized intervention derived from the ETNA3 study used in this research paper allowed the tasks to be constantly updated by the trainers, who always focused on patients' needs. This work encourages health professionals to consider their patients' needs and preferences for building person-centered care based on best practices. However, this interventional rehabilitation program requires the presence of expert specialists to direct and personalize the treatment sessions. The small number of specialists assigned to meet the steadily increasing demand on the part of patients has forced them to opt for group interventions, reducing treatment effectiveness.

Our study has certain limitations: 1) The study was conducted at a single center, meaning that the characteristics of the population may not be representative of the entire Mexican population with AD. 2) This program requires trained personnel to conduct the sessions and needs committed caregivers to accompany and stimulate the patient during the various stages of the disease. 3) The post-treatment evaluations of the outcomes of the program did not observe statistically significant differences, due to the sample size and the fact that the program had to be interrupted due to the health emergency caused by Covid-19.

The strengths of our study include follow-up for an extended period (twelve months) focusing on each patient's specific needs and those of their caregivers. This study was an evidence-based intervention.

# CONCLUSION

This study describes the feasibility and acceptability of a personalized intervention program based on the ETNA 3 study in Mexican subjects with mild dementia and their caregivers. Although the sample size did not yield positive results concerning the effectiveness of the intervention, several subjects reported improved cognition and function. Additional trials that consider the need for trained therapists and caregiver support to achieve tangible cognitive and functional changes are warranted.

# **Funding**

None.

# Conflict of interest

The authors have no conflicts of interest to declare.

# **Acknowledgments**

We would like to thank Dr. Alberto Ávila-Funes and Dr. Helena Amieva for their contribution to setting up the study. We are grateful for the support of the psychology graduates Samara Pérez Degante and María Alejandra Samudio Cruz, who collaborated in

the implementation of this study, and Sara Yeverino Castro and Irvin Emanuel Abarca for their valuable comments on the final manuscript.

#### **Author contributions**

S.G.A.N and M.G.I.P.H participated in drafting the manuscript, and the analysis, and interpretation of the data and literature review for content. C.O. participated in the conception and design of the study, and the acquisition, analysis, and interpretation of the data. G.G.L.A. participated in the conception and design of the study, and the data acquisition, analysis, and interpretation. M.A.A.J participated in the critical review of the content and the final approval of the version to be published.

All the authors have read and accepted the published version of the manuscript.

# **Data availability**

Technical appendix, statistical code, and dataset are available at the Dryad repository.

#### **REFERENCES**

- Aguilar-Navarro, S. G., Mimenza-Alvarado, A. J., Palacios-García, A. A., Samudio-Cruz, A., Gutiérrez-Gutiérrez, L. A., & Ávila-Funes, J. A. (2018). Validity and Reliability of the Spanish Version of the Montreal Cognitive Assessment (MoCA) for the Detection of Cognitive Impairment in Mexico [Validez y confiabilidad del MoCA (Montreal Cognitive Assessment) para el tamizaje del deterioro cognoscitivo en México]. Revista Colombiana de Psiquiatría, 47(4), 237-243. https://doi.org/10.1016/j.rcp.2017.05.003
- Alzheimer's Association. (2016). 2016 Alzheimer's disease facts and figures. Alzheimer's & Dementia, 12(4), 459-509. https://doi.org/10.1016/j.jalz.2016.03.001
- Amieva, H., Robert, P. H., Grandoulier, A. S., Meillon, C., De Rotrou, J., Andrieu, S., Berr, C., Desgranges, B., Dubois, B., Girtanner, C., Joël, M.-E., Lavallart, B., Nourhashemi, F., Pasquier, F., Rainfray, M., Touchon, J., Chêne, G., & Dartigues, J.-F. (2016). Group and individual cognitive therapies in Alzheimer's disease: the ETNA3 randomized trial. *International Psychogeriatrics*, 28(5), 707-717. https://doi.org/10.1017/s1041610215001830
- Amieva, H., Robert, P. H., Grandoulier, A. S., Meillon, C., De Rotrou, J., Andrieu, S., ... Dartigues, J. F. (2008, March 28 2013, August 1). Group and individual cognitive therapies in Alzheimer's disease: the ETNA3 randomized trial. National Library of Medicine. Identifier NCT00646269. https://classic.clinicaltrials.gov/ct2/show/NCT00646269
- Aravena, J. M., Gajardo, J., Saguez, R., Hinton, L., & Gitlin, L. N. (2022). Nonpharmacologic Interventions for Family Caregivers of People Living With Dementia in Latin-America: A Scoping Review. *American Journal of Geriatric Psychiatry*, 30(8), 859-877. https://doi.org/10.1016/j.jagp.2021.10.013
- Bahar-Fuchs, A., Clare, L., & Woods, B. (2013). Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementia. *Cochrane Database of Systematic Reviews*, 2013(6), CD003260. https://doi. org/10.1002/14651858.cd003260.pub2
- Berg-Weger, M., & Stewart, D. B. (2017). Non-Pharmacologic Interventions for Persons with Dementia. Missouri Medicine, 114(2), 116-119.
- Blampied, N. M. (1999). A legacy neglected: Restating the case for single-case research in cognitive-behaviour therapy. *Behaviour Change*, 16(2), 89-104. https://doi.org/10.1375/bech.16.2.89
- Choi, J., & Twamley, E. W. (2013). Cognitive Rehabilitation Therapies for Alzheimer's Disease: A Review of Methods to Improve Treatment Engagement and Self-Efficacy. *Neuropsychology Review*, 23(1), 48-62. https://doi. org/10.1007/s11065-013-9227-4
- Clare, L., Wilson, B. A., Carter, G., Roth, I., & Hodges, J. R. (2004). Awareness in Early-Stage Alzheimer's Disease: Relationship to Outcome of Cognitive Rehabilitation. *Journal of Clinical and Experimental Neuropsychology*, 26(2), 215-226. https://doi.org/10.1076/jcen.26.2.215.28088

- Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gombein, J. (1994). The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. *Neurology*, 44(12), 2308-2314. https://doi.org/10.1212/wnl.44.12.2308
- Custodio, N., Lira, D., Herrera-Perez, E., Nuñez Del Prado, L., Parodi, J., Guevara-Silva, E., Castro-Suarez, S., Mar, M., Montesinos, R., & Cortijo, P. (2014). Informal caregiver burden in middle-income countries: Results from Memory Centers in Lima-Peru. *Dementia & Neuropsychologia*, 8(4), 376-383. https://doi.org/10.1590/S1980-57642014DN84000012
- DeTure, M. A., & Dickson, D. W. (2019). The neuropathological diagnosis of Alzheimer's disease. *Molecular Neurodegeneration*, 14(1), 32. https://doi. org/10.1186/s13024-019-0333-5
- Dexter, F. (2013). Wilcoxon-Mann-Whitney test used for data that are not normally distributed. Anesthesia and Analgesia, 117(3), 537-538. https://doi.org/10.1213/ ANE.0b013e31829ed28f
- Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. *Journal of Psychiatric Research*, 12(3), 189-198. https://doi.org/10.1016/0022-3956(75)90026-6
- Freitas, S., Simões, M. R., Alves, L., & Santana, I. (2013). Montreal cognitive assessment: validation study for mild cognitive impairment and Alzheimer disease. Alzheimer Disease and Associated Disorders, 27(1), 37-43. https://doi. org/10.1097/WAD.0b013e3182420bfe
- Gebrie, M. H., & Ford, J., (2019). Depressive symptoms and dietary non-adherence among end stage renal disease patients undergoing hemodialysis therapy: systematic review. BMC Nephrology, 20(1), 429. https://doi.org/10.1186/ s12882-019-1622-5
- Gélinas, I., Gauthier, L., McIntyre, M., & Gauthier, S. (1999). Development of a Functional Measure for Persons With Alzheimer's Disease: The Disability Assessment for Dementia. *The American Journal of Occupational Therapy*, 53(5), 471-481. https://doi.org/10.5014/ajot.53.5.471
- Hachinski, V., Oveisgharan, S., Romney, A. K., & Shankle, W. R. (2012). Optimizing the Hachinski Ischemic Scale. Archives of Neurology, 69(2), 169-175. https:// doi.org/10.1001/archneurol.2011.1698
- Huang, H. C., Chen, Y. T., Chen, P. Y., Huey-Lan Hu, S., Liu, F., Kuo, Y. L., & Chiu, H. Y. (2015). Reminiscence Therapy Improves Cognitive Functions and Reduces Depressive Symptoms in Elderly People With Dementia: A Meta-Analysis of Randomized Controlled Trials. *Journal of the American Medical Directors Association*, 16(12), 1087-1094. https://doi.org/10.1016/j.jamda.2015.07.010
- Hubbard, G., O'Carroll, R., Munro, J., Mutrie, N., Haw, S., Mason, H., & Treweek, S. (2016). The feasibility and acceptability of trial procedures for a pragmatic randomised controlled trial of a structured physical activity intervention for people diagnosed with colorectal cancer: findings from a pilot trial of cardiac rehabilitation versus usual care (no rehabilitation) with an embedded qualitative study. *Pilot and Feasibility Studies*, 2, 51. https://doi.org/10.1186/s40814-016-0090-y
- Jeong, J. H., Na, H. R., Choi, S. H., Kim, J., Na, D. L., Seo, S. W., Chin, J., Park, S. A., Kim, E.-J., Han, H. J., Han, S.-H., Yoon, S. J., Lee, J.-H., Park, K. W., Moon, S. Y., Park, M. H., Choi, M. S., Han, I.-W., Lee, J. H., ... Kim, J. Y. (2016). Group- and Home-Based Cognitive Intervention for Patients with Mild Cognitive Impairment: A Randomized Controlled Trial. *Psychotherapy and Psychosomatics*, 85(4), 198-207. https://doi.org/10.1159/000442261
- Kurth, S., Wojtasik, V., Lekeu, F., Quittre, A., Olivier, C., Godichard, V., Bastin, C., & Salmon, E. (2021). Efficacy of Cogitive Rehabilitation Versus Usual Treatment at Home in Patients With Early Stages of Alzheimer Disease. *Journal of Geriatric Psychiatry and Neurology*, 34(3), 209-215. https://doi.org/10.1177/0891988720924721
- Livingston, G., Kelly, L., Lewis-Holmes, E., Baio, G., Morris, S., Patel, N., Omar, R. Z., Katona, C., & Cooper, C. (2014). Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. *British Journal of Psychiatry*, 205(6), 436-442. https://doi.org/10.1192/bjp. bp.113.141119
- Logsdon, R. G., & Teri, L. (2018). Quality of life in dementia: Conceptualization, measurement, and psychosocial treatment implications. In G. E. Smith & S. T. Farias (Eds.). APA Handbook of Dementia (pp. 237-248). https://doi.org/10.1037/0000076-012
- Lyketsos, C. G., Lopez, O., Jones, B., Fitzpatrick, A. L., Breitner, J., & DeKosky, S. (2002). Prevalence of Neuropsychiatric Symptoms in Dementia and Mild

- Cognitive Impairment: results from the cardiovascular health study. *JAMA*, 288(12), 1475-1483. https://doi.org/10.1001/jama.288.12.1475
- McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., Mohs, R. C., Morris, J. C., Rossor, M. N., Scheltens, P., Carrillo, M. C., Thies, B., Weintraub, S., & Phelps, C. H. (2011). The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia, 7(3), 263-269. https://doi.org/10.1016/j. jalz.2011.03.005
- Meyer, C., & O'Keefe, F. (2018). Non-pharmacological interventions for people with dementia: A review of reviews. *Dementia*, 19(6), 1927-1954. https://doi. org/10.1177/1471301218813234
- Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., Al Hamad, H., Alahdab, F., Alanezi, F. M., Alipour, V., Almustanyir, S., Amu, H., Ansari, I., Arabloo, J., Ashraf, T., ... Vos, T. (2022). Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. *The Lancet Public Health*, 7(2), e105-e125. https://doi.org/10.1016/s2468-2667(21)00249-8
- Nitrini, R., Barbosa, M. T., Dozzi-Brucki, S. M., Yassuda, M. S., & Caramelli, P. (2020). Current trends and challenges on dementia management and research in Latin America. *Journal of Global Health*, 10(1), 010362. https://doi.org/10.7189/jogh.10.010362
- Orsmond, G. I., & Cohn, E. S. (2015). The Distinctive Features of a Feasibility Study: Objectives and Guiding Questions. OTJR: Occupation, Participation and Health, 35(3), 169-177. https://doi.org/10.1177/1539449215578649
- Petriwskyj, A., Parker, D., Brown-Wilson, C., & Gibson, A. (2016). Evaluation of Subscription-based Culture Change Models in Care Settings: Findings From a Systematic Review. *The Gerontologist*, 56(4), e46-e62. https://doi.org/10.1093/ geront/gnw012
- Ralph, S. J., & Espinet, A. J. (2018). Increased All-Cause Mortality by Antipsychotic Drugs: Updated Review and Meta-Analysis in Dementia and General Mental Health Care. *Journal of Alzheimer's Disease Reports*, 2(1), 1-26. https://doi. org/10.3233/adr-170042
- Sachdev, P. S., Blacker, D., Blazer, D. G., Ganguli, M., Jeste, D. V., Paulsen, J. S., & Petersen, R. C. (2014). Classifying neurocognitive disorders: the DSM-5 approach. *Nature Reviews Neurology*, 10(11), 634-642. https://doi.org/10.1038/ nmeurol.2014.181
- Shigihara, Y., Hoshi, H., Shinada, K., Okada, T., & Kamada, H. (2020). Non-pharmacological treatment changes brain activity in patients with dementia. Scientific Reports, 10(1), 6744. https://doi.org/10.1038/s41598-020-63881-0
- Thomas, G. (2011). A typology for the case study in social science following a review of definition, discourse, and structure. *Qualitative Inquiry*, 17(6), 511-521. https://doi.org/10.1177/1077800411409884
- Trivedi, R. B., Szarka, J. G., Beaver, K., Brousseau, K., Nevins, E., Yancy, W. S., Slade, A., & Voils, C. I. (2013). Recruitment and retention rates in behavioral trials involving patients and a support person: A systematic review. *Contemporary Clinical Trials*, 36(1), 307-318. https://doi.org/10.1016/j.cct.2013.07.009
- Wang, L. Y., Pei, J., Zhan, Y. J., & Cai, Y. W. (2020). Overview of Meta-Analyses of Five Non-pharmacological Interventions for Alzheimer's Disease. Frontiers in Aging Neuroscience, 12, 594432. https://doi.org/10.3389/fnagi.2020.594432
- Wigfield, A., & Eccles, J. S. (2000). Expectancy–Value Theory of Achievement Motivation. Contemporary Educational Psychology, 25(1), 68-81. https://doi. org/10.1006/ceps.1999.1015
- Wilson, B. A. (2002). Towards a comprehensive model of cognitive rehabilitation. Neuropsychological Rehabilitation, 12(2), 97-110. https://doi. org/10.1080/09602010244000020
- Yesavage, J. A., Brink, T., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982). Development and validation of a geriatric depression screening scale: A preliminary report. *Journal of Psychiatric Research*, 17(1), 37-49. https://doi.org/10.1016/0022-3956(82)90033-4
- Zarit, S. H., Todd, P. A., & Zarit, J. M. (1986). Subjective Burden of Husbands and Wives as Caregivers: A Longitudinal Study. *The Gerontologist*, 26(3), 260-266. https://doi.org/10.1093/geront/26.3.260